Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years

Published Date:

November 11, 2011

Status:

superseded

| This document has been replaced by: Update on recommendations for use of herpes zoster vaccine

Source:

MMWR. Morbidity and mortality weekly report. 2011; 60(44):1528.

Language:

English

[HTML]

This is an HTML document so it cannot be previewed.

To open, click the "View" button.

Details:

Keywords:

[+]

Pubmed ID:

22071592

Description:

Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older. In March 2011, the Food and Drug Administration (FDA) approved the use of Zostavax in adults aged 50 through 59 years. In June 2011, the Advisory Committee on Immunization Practices (ACIP) declined to recommend the vaccine for adults aged 50 through 59 years and reaffirmed its current recommendation that herpes zoster vaccine be routinely recommended for adults aged 60 years and older.

Document Type:

Journal Article

Collection(s):

Guidelines and Recommendations

Supporting Files:

No Additional Files

No Related Documents.

You May Also Like:

Update on recommendations for use of herpes zoster vaccine

Personal Author:

Hales, Craig M.; Harpaz, Rafael; Ortega-Sanchez, Ismael; Bialek, Stephanie R.;

Corporate Author:

United States. Advisory Committee on Immunization Practices.. National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases..

Published:

August 22, 2014

Series:

MMWR. Morbidity and mortality weekly report, Vol. 63, no. 33, p. 729-31

Description:

Herpes zoster vaccine (Zostavax [Merck & Co., Inc.]) was licensed in 2006 and recommended by the Advisory Committee on Immunization Practices (ACIP) in 2008 for prevention of herpes zoster (shingles) and its complications among adults aged ≥60 year...

Status:

current

File Type:

[PDF - 195.85 KB]
Update on Recommendations for Use of Herpes Zoster Vaccine

Personal Author:

Hales, Craig M.; Harpaz, Rafael; Ortega-Sanchez, Ismael; Bialek, Stephanie R.;

Corporate Author:

United States. Advisory Committee on Immunization Practices.

Published:

Aug 22 2014

Source:

MMWR Morb Mortal Wkly Rep. 2014; 63(33):729-731.

Description:

Herpes zoster vaccine (Zostavax [Merck & Co., Inc.]) was licensed in 2006 and recommended by the Advisory Committee on Immunization Practices (ACIP) in 2008 for prevention of herpes zoster (shingles) and its complications among adults aged ≥60 year...

File Type:

[PDF - 109.32 KB]
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

Personal Author:

Dooling, Kathleen L.; Guo, Angela; Patel, Manisha; Lee, Grace M.; Moore, Kelly; Belongia, Edward A.; Harpaz, Rafael;

Corporate Author:

United States. Advisory Committee on Immunization Practices.

Published:

Jan 26 2018

Source:

MMWR Morb Mortal Wkly Rep. 67(3):103-108.; Published also as: Am J Transplant. 2018 Mar;18(3):756-762. doi: 10.1111/ajt.14683. (PMID: 29462512).;

Description:

On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01|), was a...

File Type:

[PDF - 114.29 KB]
Herpes Zoster Vaccination update : introduction

Personal Author:

Belongia, Edward A.

Corporate Author:

United States. Advisory Committee on Immunization Practices. Zoster Working Group.. Marshfield Clinic Research Institute..

Conference Author:

United States. Advisory Committee on Immunization Practices. Meeting (2018 June 20-21 : Atlanta, GA)

Published:

8/9/18

Series:

ACIP meeting Herpes Zoster Vaccine

Description:

Presentations June 2018 Day 1 : Publication date from document properties.

File Type:

[PDF - 547.59 KB]
Manual for the surveillance of vaccine-preventable diseases. Chapter 17: Varicella

Personal Author:

Lopez, Adriana S.; Schmid, D Scott; Bialek, Stephanie R.;

Corporate Author:

National Center for Immunization and Respiratory Diseases (U.S.)

Published:

Oct 2015

Series:

Manual for the surveillance of vaccine-preventable diseases ; chapter 17

Description:

Chapter 17 of: Manual for the surveillance of vaccine-preventable diseases. 5th edition, 2011. : Varicella (chickenpox) is a febrile rash illness resulting from primary infection with the varicella-zoster virus (VZV). Humans are the only source of in...

File Type:

[PDF - 392.24 KB]